All In Biotech

Drug Trial Radar · NCT02740712

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

A Phase 1, Open-label, Multiple-probe Drug-drug Interaction Study to Determine the Effect of Rucaparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, and Digoxin in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Apr 2016

Primary completion

Mar 2017

Study completion Sep 2019

Sponsor

Lead sponsor
pharmaand GmbHIndustry
Sponsor type
Industry
First posted
Apr 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.

Conditions

  • Neoplasms

Interventions

  • CaffeineDrug

    200 mg (4 x 50mg) Tablet

  • WarfarinDrug

    10 mg (2 x 5mg) Tablet

  • OmeprazoleDrug

    40 mg Tablet

  • MidazolamDrug

    5 mg/mL

  • digoxinDrug

    .25 mg Tablet

  • Vitamin KDrug

    10 mg Tablet

  • RucaparibDrug

    200 \& 300 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time dataTime frame: Days 1-5 and Days 12-16
  2. PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time dataTime frame: Days 1-5 and Days 12-16

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Med Polonia

    Poznan, Poland

  • Zachodniopomorskie Centrum Onkologii Centrum Innowacji

    Szczecin, Poland

  • BioVirtus Research Site

    Kajetany, Mokra 7, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.